1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Diagnostic measures for the Cox regression model with missing covariates

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We investigate diagnostic measures for assessing the influence of observations and model misspecification on the Cox regression model when there are missing covariate data. Our diagnostics include case-deletion measures, conditional martingale residuals, and score residuals. The Q-distance is introduced to examine the effects of deleting individual observations on the estimates of finite- and infinite-dimensional parameters. Conditional martingale residuals are used to construct goodness-of-fit statistics for testing misspecification of the model assumptions. A resampling method is developed to approximate the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$p$\end{document} -values of the goodness-of-fit statistics. We conduct simulation studies to evaluate our methods, and analyse a real dataset to illustrate their use.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

          To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC). Stage IIIB/IV NSCLC patients were randomized to arm A (four cycles of carboplatin at an area under the curve of 6 and paclitaxel 200 mg/m(2) every 21 days) or arm B (continuous treatment with carboplatin/paclitaxel until progression). At progression, all patients on both arms were to receive second-line weekly paclitaxel at 80 mg/m(2)/wk. The primary end points were survival and quality of life (QOL). Two hundred thirty patients were randomized. Fifty-seven percent of arm A patients completed four courses of therapy. In the 116 arm B patients, the median number of cycles delivered was four (range, zero to 19 cycles). Forty-two percent received five or more cycles; 18% received eight or more cycles. Overall response rates were 22% and 24% for arms A and B, respectively (P =.80). Median survival time and 1-year survival rates were 6.6 months and 28% for arm A and 8.5 months and 34% for arm B, respectively (log-rank P =.63). Rates of hematologic and nonhematologic toxicity were similar between the two arms, except for neuropathy. The rate of grade 2 to 4 neuropathy increased from 19.9% (95% confidence interval [CI], 13.6% to 26.2%) at cycle 4 to 43% (95% CI, 28.6% to 57.4%) at cycle 8. There were no differences in QOL. Only 45% of patients received second-line therapy (42% in arm A v 47% in arm B, P =.42). This study shows no overall benefit in survival, response rates, or QOL to continuing treatment with carboplatin/paclitaxel beyond four cycles in advanced NSCLC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Regression models and life‐tables (with discussion)

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Missing covariates in generalized linear models when the missing data mechanism is non-ignorable

                Bookmark

                Author and article information

                Journal
                Biometrika
                Biometrika
                biomet
                biomet
                Biometrika
                Oxford University Press
                0006-3444
                1464-3510
                December 2015
                04 November 2015
                1 December 2016
                : 102
                : 4
                : 907-923
                Affiliations
                Department of Biostatistics, University of North Carolina at Chapel Hill, 3109 McGavran-Greenberg Hall, CB #7420, Chapel Hill, North Carolina 27516, U.S.A. hzhu@ 123456bios.unc.edu
                Department of Statistics, University of Connecticut, 215 Glenbrook Road, U-4120, Storrs, Connecticut 06269, U.S.A. ming-hui.chen@ 123456uconn.edu
                Author notes
                Article
                asv047
                10.1093/biomet/asv047
                4760115
                26903666
                4fb3f518-1421-43dc-aa77-fdb657e6237b
                © 2015 Biometrika Trust
                History
                : August 2013
                : July 2015
                Funding
                Funded by: U.S. National Institutes of Health
                Funded by: National Science Foundation , open-funder-registry 10.13039/100000001;
                Categories
                Articles

                case-deletion measure,conditional martingale residual,goodness-of-fit statistic,model misspecification

                Comments

                Comment on this article